GLP-1 medical weight loss in Hunstville, Alabama
The Complete Guide To GLP-1 Medications
TL;DR
GLP-1 medications like semaglutide and tirzepatide are the most effective non-surgical obesity treatment available today. They work by changing hunger signaling in the brain, not through willpower. Clinical trials show average weight loss of 15 to 21 percent of body weight, depending on the drug and dose. They require ongoing use to keep the weight off, they don't fit every patient, and they work best inside a supervised medical program rather than a one-off prescription.
What GLP-1 Medications Are, and Why They Work
GLP-1 stands for glucagon-like peptide-1, a hormone your gut already produces. When you eat, cells in your small intestine release it. From there it travels to the pancreas, the brain, and the stomach, doing several jobs at once. It tells the pancreas to release insulin when glucose rises. It slows how fast your stomach empties. And it signals hunger centers in the brain, in the hypothalamus and brainstem, to ease off.
In obesity, this system doesn't run the way it should. GLP-1 levels can run lower. The brain's response to fullness gets blunted. The signal that tells you you've had enough food doesn't land the way it's supposed to. GLP-1 receptor agonists are synthetic versions built to bind those same receptors and activate them far more strongly than the natural hormone does. Patients eat less because the hormonal signal driving appetite has changed, not because they're forcing themselves to.
A lot of patients describe a drop in what's now commonly called "food noise," the constant background hum of thinking about food. That effect has a real physiological basis. These drugs quiet hypothalamic hunger signals. They also slow gastric emptying, so food sits in the stomach longer and fullness lasts. The two effects work together.
Tirzepatide, the active ingredient in Mounjaro and Zepbound, adds a second mechanism on top of this. It activates GIP receptors as well as GLP-1 receptors. GIP, short for glucose-dependent insulinotropic polypeptide, is a separate gut hormone involved in fat metabolism and insulin sensitivity. Activating both pathways at once produces greater weight loss than GLP-1 activity alone, which is what the SURMOUNT-1 trial found.
Ozempic, Wegovy, Mounjaro, and Zepbound: Sorting Out the Names
The brand names cause a lot of confusion. Ozempic and Wegovy are the same drug, semaglutide, at different doses for different uses. Mounjaro and Zepbound have that same relationship with tirzepatide.
Ozempic is FDA-approved for type 2 diabetes, dosed up to 1 mg weekly. Wegovy is the same molecule at 2.4 mg weekly, approved specifically for weight management. Patients using Ozempic off-label for weight loss are typically on a lower dose than what the obesity trials studied. Wegovy's dose is what the STEP trial results are built on, which matters when comparing personal results to published data.
Mounjaro is tirzepatide approved for diabetes. Zepbound is the same drug approved for weight management, and more recently for obstructive sleep apnea in adults with obesity. The SURMOUNT trial data reflects Zepbound's weight-loss doses of 10 or 15 mg weekly.
What the Clinical Trials Actually Show
The STEP trials are where semaglutide 2.4 mg earned its track record. STEP 1, led by Wilding and colleagues and published in the New England Journal of Medicine in 2021, found participants without diabetes lost an average of 14.9% of body weight at 68 weeks, against 2.4% in the placebo group. About a third lost 20% or more. About a third lost less than 10%. The range matters as much as the average.
Tirzepatide's SURMOUNT-1 trial, published in the same journal in 2022 by Jastreboff and colleagues, posted bigger numbers: 15.0% mean weight loss at 5 mg, 19.5% at 10 mg, 20.9% at 15 mg. The 2025 SURMOUNT-5 trial put the two drugs head-to-head directly. Tirzepatide produced 20.2% mean weight loss against 13.7% for semaglutide over 72 weeks, a 6.5 percentage point gap that's clinically meaningful.
One number gets far less attention online than it deserves: what happens after you stop. STEP 4 showed patients who discontinued semaglutide after losing weight regained a large share of it. SURMOUNT-4 found the same pattern with tirzepatide. Participants switched to placebo after 36 weeks regained 14% of body weight on average, while those who stayed on the drug lost another 5.5%. That's the expected behavior of a chronic disease once treatment stops, not a side effect of the drug.
Who These Medications Fit, and Who They Don't
The FDA has cleared Wegovy and Zepbound for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition like high blood pressure, high cholesterol, or type 2 diabetes. That's the label. Real-world candidacy involves more than where a patient lands on that scale.
GLP-1 medication makes sense for patients with a moderate obesity burden, the ability to sustain long-term treatment, no contraindications, and genuine willingness to stay on it. It works best inside a supervised program, not as a prescription handed over and forgotten. The patients who do best tend to have consistent follow-through, regular monitoring, and realistic expectations about what the drug can and can't do on its own.
There are hard stops. Both Wegovy and Zepbound carry a boxed warning for thyroid C-cell tumors, based on findings in animal studies. Neither should be used in patients with a personal or family history of medullary thyroid carcinoma or MEN2. A history of pancreatitis calls for careful evaluation before starting either drug. Talk to your physician about these before starting, not after.
GLP-1 medication isn't the right first move for patients carrying severe obesity with serious complications who need durable, lasting results. A BMI over 40, or over 35 with conditions like sleep apnea, type 2 diabetes, or heart disease, often represents a disease burden bigger than medication alone can handle, especially once real-world discontinuation rates are factored in.
Finding the Right Provider
The number of places writing GLP-1 prescriptions has grown faster than the quality of the care behind them. Telehealth platforms and med spas across the country, including plenty serving patients in Alabama, will write a prescription off a short online form with no real exam. Obesity is a chronic disease with real complexity. A prescription with no evaluation, no monitoring, and no plan for what comes next leaves a patient holding a medication and little else.
Real physician supervision looks different. It starts with a baseline metabolic evaluation, a clear picture of health history and contraindications, ongoing monitoring while on the drug, and a plan for six months, twelve months, and beyond. A physician who takes this seriously will say plainly if the response isn't strong enough to justify staying the course, and will have more than a prescription pad to offer if it isn't.
Patients who reach us after starting GLP-1 through a telehealth service or med spa usually have the same gap: they know their weight has changed, but they don't know their metabolic trajectory, whether their results are typical, or what comes next if the medication plateaus. Our practice offers physician-supervised GLP-1 management built around exactly that gap, paired with full access to surgical evaluation if medication isn't enough on its own.
A few warning signs worth watching for in any GLP-1 provider: no in-person or video evaluation before the first prescription, no baseline labs, no real discussion of contraindications, no monitoring plan, and no path to bariatric surgery if medication falls short. One of these is worth a question. All of them together is worth walking away.
Side Effects: What to Expect and What to Watch For
GI side effects are the most common reason patients stop. Nausea, vomiting, diarrhea, and constipation all show up in the data. Most were mild to moderate in the clinical trials and tended to cluster around dose increases, often easing as the body adjusts. Even so, 5 to 7 percent of participants in the STEP and SURMOUNT trials stopped because of GI side effects.
Managing it well comes down to a few things: slow dose increases, smaller meals, avoiding high-fat foods that delay gastric emptying further, and staying hydrated. Our approach is to slow down or hold a dose when GI symptoms start interfering with daily life. The goal is the most effective dose a patient can actually tolerate, not the highest dose on the label.
Less common but more serious effects include gallbladder problems, possible worsening of diabetic eye disease in patients who already have retinopathy, and rare cases of pancreatitis. Resting heart rate can tick up slightly. The thyroid warning deserves its own mention: in rodent studies, GLP-1 receptor agonists caused thyroid C-cell tumors. That hasn't been confirmed in humans, but the FDA still requires the boxed warning, and the drugs remain contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or MEN2. Any new lump in the neck or trouble swallowing needs evaluation.
What We Tell Patients in Consultation
GLP-1 medications are the biggest shift in obesity medicine in a generation. We've watched patients in our own practice lose 15 to 20 percent of their body weight on these drugs, results that would have been unthinkable from an injection fifteen years ago.
The most effective treatment in general and the right treatment for a given patient aren't always the same thing. Our practice prescribes GLP-1 medications, and we perform bariatric surgery. That means there's no financial incentive pulling us toward one option over the other. What we have instead is a direct view of both paths: patients who do remarkably well on medication alone, patients who plateau and need more, and patients whose disease burden points to surgery from the start.
Patients with type 2 diabetes tend to lose less weight on these medications than patients without it, a pattern both the STEP 2 and SURMOUNT-2 trials showed clearly. We talk about that openly before anyone starts. Trial numbers are averages. Some patients do noticeably better. Some plateau sooner.
Frequently Asked Questions
Is Ozempic the same as Wegovy?
Same drug, semaglutide, at different doses for different FDA-approved uses. Ozempic is approved for type 2 diabetes, dosed up to 1 mg weekly. Wegovy is approved for weight management at 2.4 mg weekly, the dose behind the STEP trial results. Using Ozempic off-label for weight loss usually means a lower dose than what the obesity research is based on.
How much weight will I actually lose?
In clinical trials, semaglutide 2.4 mg produced average weight loss of about 14.9% at 68 weeks (STEP 1, Wilding et al., NEJM 2021). Tirzepatide produced average losses of 15 to 21 percent depending on dose (SURMOUNT-1, Jastreboff et al., NEJM 2022), outperforming semaglutide by about 6.5 percentage points in a head-to-head trial (SURMOUNT-5, Aronne et al., NEJM 2025). These are averages. Individual results vary a lot.
Will I gain the weight back if I stop?
Most patients regain a significant share of what they lost. Weight regain after stopping reflects how a chronic condition behaves, not a personal failure. STEP 4 showed substantial regain after semaglutide was discontinued. SURMOUNT-4 showed the same with tirzepatide. Long-term, often indefinite, use is usually what it takes to hold onto results.
Is tirzepatide better than semaglutide?
The trial data favor tirzepatide for raw weight loss. SURMOUNT-5, the first direct head-to-head trial in people without diabetes, found tirzepatide produced 20.2% mean weight loss against 13.7% for semaglutide at 72 weeks (Aronne et al., NEJM 2025). When both are accessible and covered, tirzepatide is usually the first choice for patients prioritizing maximum weight loss. Cost and insurance access complicate that choice for many patients.
Can I get these medications from a telehealth provider or med spa?
Legally, yes. Clinically, caution is warranted. Most of these services hand patients a prescription, not a program. There's typically no baseline metabolic evaluation, no monitoring for side effects, and rarely a plan for what happens if a patient plateaus or needs to stop.
Who shouldn't take GLP-1 medications?
A personal or family history of medullary thyroid carcinoma or MEN2 rules these out entirely. A history of pancreatitis calls for careful evaluation first. GLP-1 medication isn't the right first-line treatment for patients with severe obesity whose disease burden is likely to outpace what medication alone can manage.
What is the SELECT trial, and why does it matter?
SELECT was a large cardiovascular outcomes trial of semaglutide 2.4 mg in adults with obesity and existing cardiovascular disease but no diabetes (Lincoff et al., NEJM 2023). It found a significant drop in major cardiovascular events in that group. It's the strongest evidence to date that weight-loss doses of semaglutide carry cardiovascular benefit beyond the weight loss itself.
Wondering whether GLP-1 medication is the right place to start?
We see patients at every stage, newly researching, already on medication and plateaued, or ready to talk through surgery. A consultation is the clearest way to find out where you actually stand.
Sources
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989–1002. pubmed.ncbi.nlm.nih.gov/33567185
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205–216. pubmed.ncbi.nlm.nih.gov/35658024
- Aronne LJ, et al. Tirzepatide vs. Semaglutide for Obesity (SURMOUNT-5). New England Journal of Medicine. 2025. pubmed.ncbi.nlm.nih.gov/40353578
- Aronne LJ, et al. Continued Treatment with Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024;331(1):38–48. pubmed.ncbi.nlm.nih.gov/38078870
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023;389(24):2221–2232. pubmed.ncbi.nlm.nih.gov/37952131
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018;27(4):740–756. pubmed.ncbi.nlm.nih.gov/29617641
- FDA Prescribing Information — Wegovy (semaglutide injection). U.S. Food and Drug Administration. 2021. accessdata.fda.gov
- FDA Prescribing Information — Zepbound (tirzepatide injection). U.S. Food and Drug Administration. 2023. accessdata.fda.gov